ACE2 and COVID-19: A paired Wilcoxon test comparing NRP1 and ACE2 expression within each sample showed a non-significant trend in controls (p = 0.0625), while a statistically significant difference was observed in COVID-19 patients (p = 0.03125), with NRP1 consistently exceeding ACE2 levels.